How and when environmental agents and dietary factors affect the course of Alzheimer's disease: The "LEARn" model (Latent Early-Life Associated Regulation) may explain the triggering of AD

Current Alzheimer Research

Volumn 4, Issue 2, 2007, Pages 219-228

  Lahiri, Debomoy K ^a   Maloney, Bryan ^a   Basha, Md Riyaz ^b   Yuan, Wen Ge ^a   Zawia, Nasser H ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Aging; Cholesterol; Dementia; Development; Diet; Epigenetics; Gene regulation; LEARn; Metal; Methylation; Promoter; Psychiatric disorders; Risk factors

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; CHOLESTEROL; CYTOKINE; GUANOSINE; HEAVY METAL; TAU PROTEIN;

ALZHEIMER DISEASE; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE COURSE; DNA METHYLATION; DNA SEQUENCE; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE CONTROL; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; REVIEW;

AGE OF ONSET; ALZHEIMER DISEASE; ANIMALS; DIET; ENVIRONMENT; HUMANS; MODELS, BIOLOGICAL; RISK FACTORS; TIME FACTORS;

EID: 33846983823     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507780362164     Document Type: Review

References (139)

1. von Strauss E, Viitanen M, De Ronchi D, Winblad B and Fratiglioni L. Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol 56: 587-592 (1999).
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA and Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60: 1119-1122 (2003).
3. Hoyert DL, Heron MP, Murphy SL and Kung HC. Deaths: final data for 2003. Natl Vital Stat Rep 54: 1-120 (2006).
4. Brookmeyer R and Gray S. Methods for projecting the incidence and prevalence of chronic diseases in aging populations: application to Alzheimer's disease. Stat Med 19: 1481-1493 (2000).
5. Wimo A, Jonsson L and Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21: 175-181 (2006).
6. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117 (2005).
7. Gruffydd E and Randle J. Alzheimer's disease and the psychosocial burden for caregivers. Community Pract 79: 15-18 (2006).
8. Dixon S, Walker M and Salek S. Incorporating carer effects into economic evaluation. Pharmacoeconomics 24: 43-53 (2006).
9. Prigerson HG. Costs to society of family caregiving for patients with end-stage Alzheimer's disease. N Engl J Med 349: 1891-1892 (2003).
10. Statistics about Alzheimer's disease. http://www.alz.org/AboutAD/ statistics.asp, Alzheimer's Association.
11. Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62: 192-195 (2005).
12. LaFerla FM and Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11: 170-176 (2005).
13. Hardy JA and Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185 (1992).
14. Selkoe DJ. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem Res 28: 1705-1713 (2003).
15. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
16. Lahiri DK, Farlow MR, Greig NH and Sambamurti K. Current drug targets for Alzheimer's disease treatment. Drug Devel Res 56: 267-281 (2002).
17. Jacobsen JS, Reinhart P and Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2: 612-626 (2005).
18. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, et al . A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 3: 81-90 (2006).
19. Lee HG, Petersen RB, Zhu X, Honda K, Aliev G, Smith MA, et al. Will preventing protein aggregates live up to its promise as prophylaxis against neurodegenerative diseases? Brain Pathol 13: 630-638 (2003).
20. Xia W, Ostaszewski BL, Kimberly WT, Rahmati T, Moore CL, Wolfe MS, et al. FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex. Neurobiol Dis 7: 673-681 (2000).
21. Hall K, Gureje O, Gao S, Ogunniyi A, Hui SL, Baiyewu O, et al . Risk factors and Alzheimer's disease: a comparative study of two communities. Aust N Z J Psychiatry 32: 698-706 (1998).
22. Wilson RS, Bennett DA, Bienias JL, Mendes de Leon CF, Morris MC and Evans DA. Cognitive activity and cognitive decline in a biracial community population. Neurology 61: 812-816 (2003).
23. Scarmeas N and Stern Y. Cognitive reserve and lifestyle. J Clin Exp Neuropsychol 25: 625-633 (2003).
24. Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, et al . Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J Neural Transm 111: 523-536 (2004).
25. Sambamurti K, Granholm AC, Kindy MS, Bhat NR, Greig NH, Lahiri DK, et al . Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets 5: 517-528 (2004).
26. Evans DA, Beckett LA, Field TS, Feng L, Albert MS, Bennett DA, et al. Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA 277: 822-824 (1997).
27. Levy-Lahad E, Lahad A, Wijsman EM, Bird TD and Schellenberg GD. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann Neurol 38: 678-680 (1995).
28. Edland SD, Wavrant-De Vriese F, Compton D, Smith GE, Ivnik R, Boeve BF, et al. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett 345: 21-24 (2003).
29. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 164: 1425-1434 (2004).
30. Ling Y, Morgan K and Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int J Biochem Cell Biol 35: 1505-1535 (2003).
31. Saunders AJ, Bertram L, Mullin K, Sampson AJ, Latifzai K, Basu S, et al. Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet 12: 2765-2776 (2003).
32. Eckman EA and Eckman CB. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33: 1101-1105 (2005).
33. Mui S, Briggs M, Chung H, Wallace RB, Gomez-Isla T, Rebeck GW, et al . A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele. Neurology 47: 196-201 (1996).
34. Artiga MJ, Bullido MJ, Frank A, Sastre I, Recuero M, Garcia MA, et al. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet 7: 1887-1892 (1998).
35. Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D, et al. Pronounced impact of Th1/E47cs mutation compared with - 491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet 7: 1511-1516 (1998).
36. Lahiri DK, Wavrant De-Vrieze F, Ge YW, Maloney B and Hardy J. Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer's disease. Neurobiol Aging 26: 1329-1341 (2005).
37. Gabbita SP, Lovell MA and Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71: 2034-2040 (1998).
38. Lahiri DK, Xu Y, Klaunig J, Baiyewu O, Ogunniyi A, Hall K, et al . Effect of oxidative stress on DNA damage and beta-amyloid precursor proteins in lymphoblastoid cell lines from a Nigerian population. Ann N Y Acad Sci 893: 331-336 (1999).
39. Lovell MA, Gabbita SP and Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 72: 771-776 (1999).
40. Albers DS and Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. Journal of neural transmission Supplementum 59: 133-154 (2000).
41. Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, et al. Gene regulation and DNA damage in the ageing human brain. Nature 429: 883-891 (2004).
42. Apelt J, Bigl M, Wunderlich P and Schliebs R. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci 22: 475-484 (2004).
43. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, et al . Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm 112: 455-469 (2005).
44. Grilli M, Ribola M, Alberici A, Valerio A, Memo M and Spano P. Identification and characterization of a kappa B/Rel binding site in the regulatory region of the amyloid precursor protein gene. J Biol Chem 270: 26774-26777 (1995).
45. Mattson MP, Barger SW, Furukawa K, Bruce AJ, Wyss-Coray T, Mark RJ, et al . Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev 23: 47-61 (1997).
46. Lahiri DK. An region upstream of the gene promoter for the betaamyloid precursor protein interacts with proteins from nuclear extracts of the human brain and PC12 cells. Brain Res Mol Brain Res 58: 112-122 (1998).
47. Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E and Paul SM. The NF-kappaB/Rel family of proteins mediates Abetainduced neurotoxicity and glial activation. Brain Res Mol Brain Res 57: 63-72 (1998).
48. Bales KR, Du Y, Holtzman D, Cordell B and Paul SM. Neuroinflammation and Alzheimer's disease: critical roles for cytokine/ Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging 21: 427-432 (2000).
49. Yoshiyama Y, Arai K and Hattori T. Enhanced expression of IkappaB with neurofibrillary pathology in Alzheimer's disease. Neuroreport 12: 2641-2645 (2001).
50. in 't Veld BA, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, et al . NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 19: 607-611 (1998).
51. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 16: 811-824 (2002).
52. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al . NSAIDs and enantiomers of flurbiprofen target gammasecretase and lower Abeta 42 in vivo. J Clin Invest 112: 440-449 (2003).
53. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504-7509 (2003).
54. Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma -secretase at a novel site-evidence for an allosteric mechanism. J Biol Chem 279: 43419-43426 (2004).
55. Klegeris A and McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2: 355-365 (2005).
56. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A. 103: 443-448 (2006).
57. Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, et al. Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. FASEB J 20: 788-790 (2006).
58. White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, et al . Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 842: 439-444 (1999).
59. White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, et al . The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 19: 9170-9179 (1999).
60. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Inestrosa NC and Bush AI. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological agents to neurotoxic H2O2. J Biol Chem 277: 40302-40308 (2002).
61. Simons A, Ruppert T, Schmidt C, Schlicksupp A, Pipkorn R, Reed J, et al. Evidence for a copper-binding superfamily of the amyloid precursor protein. Biochemistry 41: 9310-9320 (2002).
62. Sparks DL and Schreurs BG. Trace amounts of copper in water induce {beta}-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 100: 11193-11194 (2003).
63. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G and Camakaris J. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 279: 20378-20386 (2004).
64. Zawia NH, Sharan R, Brydie M, Oyama T and Crumpton T. Sp1 as a target site for metal-induced perturbations of transcriptional regulation of developmental brain gene expression. Brain Res Dev Brain Res 107: 291-298 (1998).
65. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25: 823-829 (2005).
66. Shastry BS. Neurodegenerative disorders of protein aggregation. Neurochem Int 43: 1-7 (2003).
67. Morgan C, Colombres M, Nunez MT and Inestrosa NC. Structure and function of amyloid in Alzheimer's disease. Prog Neurobiol 74: 323-349 (2004).
68. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741 (1999).
69. Wang ZF, Li HL, Li XC, Zhang Q, Tian Q, Wang Q, et al. Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. J Neurochem 98: 1167-1175 (2006).
70. Barker DJ, Eriksson JG, Forsen T and Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 31: 1235-1239 (2002).
71. Davuluri RV, Suzuki Y, Sugano S and Zhang MQ. CART classification of human 5′ UTR sequences. Genome Res 10: 1807-1816 (2000).
72. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 9: 2395-2402 (2000).
73. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al . Epigenetic programming by maternal behavior. Nat Neurosci 7: 847-854 (2004).
74. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA and Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr 135: 1382-1386 (2005).
75. Poirier LA and Vlasova TI. The prospective role of abnormal methyl metabolism in cadmium toxicity. Environ Health Perspect 110 Suppl 5: 793-795 (2002).
76. Takiguchi M, Achanzar WE, Qu W, Li G and Waalkes MP. Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp Cell Res 286: 355-365 (2003).
77. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 152: 1485-1492 (1995).
78. Gureje O, Ogunniyi A, Baiyewu O, Price B, Unverzagt FW, Evans RM, et al . APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol 59: 182-185 (2006).
79. Ogunniyi A, Baiyewu O, Gureje O, Hall KS, Unverzagt F, Siu SH, et al. Epidemiology of dementia in Nigeria: results from the Indianapolis-Ibadan study. Eur J Neurol 7: 485-490 (2000).
80. Salbaum JM, Weidemann A, Lemaire HG, Masters CL and Beyreuther K. The promoter of Alzheimer's disease amyloid A4 precursor gene. EMBO J 7: 2807-2813 (1988).
81. La Fauci G, Lahiri DK, Salton SR and Robakis NK. Characterization of the 5'-end region and the first two exons of the beta-protein precursor gene. Biochem Biophys Res Commun 159: 297-304 (1989).
82. Lahiri DK and Robakis NK. The promoter activity of the gene encoding Alzheimer beta-amyloid precursor protein (APP) is regulated by two blocks of upstream sequences. Brain Res Mol Brain Res 9: 253-257 (1991).
83. Quitschke WW and Goldgaber D. The amyloid beta-protein precursor promoter. A region essential for transcriptional activity contains a nuclear factor binding domain. J Biol Chem 267: 17362-17368 (1992).
84. Lahiri DK and Nall C. Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Brain Res Mol Brain Res 32: 233-240 (1995).
85. Querfurth HW, Wijsman EM, St George-Hyslop PH and Selkoe DJ. Beta APP mRNA transcription is increased in cultured fibroblasts from the familial Alzheimer's disease-1 family. Brain Res Mol Brain Res 28: 319-337 (1995).
86. Song W and Lahiri DK. Functional identification of the promoter of the gene encoding the Rhesus monkey beta-amyloid precursor protein. Gene 217: 165-176 (1998).
87. Lahiri DK, Nall C and Ge YW. Promoter activity of the betaamyloid precursor protein gene is negatively modulated by an upstream regulatory element. Brain Res Mol Brain Res 71: 32-41 (1999).
88. Lahiri DK, Song W and Ge YW. Analysis of the 5′-flanking region of the beta-amyloid precursor protein gene that contributes to increased promoter activity in differentiated neuronal cells. Brain Res Mol Brain Res 77:185-198 (2000).
89. Lahiri DK and Ge Y-W. Role of APP promoter in Alzheimer's disease: cell type specific expression of the beta-amyloid precursor protein. Ann N Y Acad Sci IN PRESS, (2004).
90. Lahiri DK, Ge YW and Maloney B. Characterization of the APP proximal promoter and 5′-untranslated regions: identification of cell-type specific domains and implications in APP gene expression and Alzheimer's disease. FASEB J 19: 653-655 (2005).
91. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S and Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 24: 865-874 (2004).
92. Ge YW, Maloney B, Sambamurti K and Lahiri DK. Functional characterization of the 5′ flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. FASEB J 18: 1037-1039 (2004).
93. Sambamurti K, Kinsey R, Maloney B, Ge YW and Lahiri DK. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 18: 1034-1036 (2004).
94. Lange-Dohna C, Zeitschel U, Gaunitz F, Perez-Polo JR, Bigl V, and Rossner S. Cloning and expression of the rat BACE1 promoter. J Neurosci Res 73:73-80 (2003).
95. Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. Faseb J 19, 739-749 (2005).
96. Lahiri DK, Maloney B and Ge YW. BACE1 gene promoter is differentially regulated: Detection of a novel promoter region for its cell type-specific regulation. J Mol Neurosci IN PRESS, (2005).
97. Lahiri DK, Maloney B and Ge Y-W. Functional Domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells. J Mol Neurosci. 29: 65-80 (2006).
98. Nowak K, Lange-Dohna C, Zeitschel U, Gunther A, Luscher B, Robitzki A, et al. The transcription factor Yin Yang 1 is an activator of BACE1 expression. J Neurochem 96: 1696-1707 (2006).
99. Chang DJ, Paik YK, Leren TP, Walker DW, Howlett GJ and Taylor JM. Characterization of a human apolipoprotein E gene enhancer element and its associated protein factors. J Biol Chem 265: 9496-9504 (1990).
100. Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J, et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 421: 105-108 (1998).
101. Lahiri DK, Alley GM, Ge YW and Du Y. Functional characterization of the 5′-regulatory region of the murine apolipoprotein gene. Ann N Y Acad Sci 973: 340-344 (2002).
102. Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C, Wang JC, Bullido MJ, et al. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 59: 59-66 (2002).
103. Ge YW, Maloney B, Alley GM and Lahiri DK. Important Differences between Human and Mouse APOE Gene Promoters: Implications in Alzheimer's Disease. J Neurochem In Submission, (2006).
104. Du Y, Chen X, Wei X, Bales KR, Berg DT, Paul SM, et al. NFkappaB mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res Mol Brain Res 136: 177-188 (2005).
105. Andreadis A, Wagner BK, Broderick JA and Kosik KS. A tau promoter region without neuronal specificity. J Neurochem 66, 2257-2263 (1996).
106. Sadot E, Heicklen-Klein A, Barg J, Lazarovici P and Ginzburg I. Identification of a tau promoter region mediating tissue-specific-regulated expression in PC12 cells. J Mol Biol 256: 805-812 (1996).
107. Heicklen-Klein A and Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem 75: 1408-1418 (2000).
108. Ge YW, Ghosh M, Song W, Maloney B and Lahiri D. Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell types. Identification of a specific 30 bp fragment in the proximal promoter region. J Neurochem 90: 1432-1444 (2004).
109. Lahiri DK, Chen D, Vivien D, Ge YW, Greig NH and Rogers JT. Role of cytokines in the gene expression of amyloid beta-protein precursor: Identification of a 5′-UTR-Binding nuclear factor and its implications in Alzheimer's disease. J Alzheimers Dis 5: 81-90 (2003).
110. Rogers JT and Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5 :535-551 (2004).
111. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92: 628-636 (2005).
112. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10: 279-288 (2002).
113. Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, et al. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 20, 7951-7963 (2000).
114. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. epub ahead of print doi:10.1096/fj.04-2637fje, (2004).
115. Lukiw WJ, Rogaev EI, Wong L, Vaula G, McLachlan DR and St George Hyslop P. Protein-DNA interactions in the promoter region of the amyloid precursor protein (APP) gene in human neocortex. Brain Res Mol Brain Res 22: 121-131 (1994).
116. Hoffman PW and Chernak JM. DNA binding and regulatory effects of transcription factors SP1 and USF at the rat amyloid precursor protein gene promoter. Nucleic Acids Res 23: 2229-2235 (1995).
117. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, et al. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 23, 3597-3606 (2003).
118. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296: 2238-2243 (2002).
119. Qiu Z, Norflus F, Singh B, Swindell MK, Buzescu R, Bejarano M, et al. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem 281: 16672-16680 (2006).
120. Chan A and Shea TB. Supplementation with apple juice attenuates presenilin-1 overexpression during dietary and genetically-induced oxidative stress. J Alzheimer's Dis 10: 353-358 (2006).
121. Pufulete M, Al-Ghnaniem R, Khushal A, Appleby P, Harris N, Gout S, et al. Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma. Gut 54: 648-653 (2005).
122. Bondy SC, Yang YE, Walsh TJ, Gie YW and Lahiri DK. Dietary modulation of age-related changes in cerebral pro-oxidant status. Neurochem Int 40: 123-130 (2002).
123. Lahiri DK, Chen D, Ge YW, Bondy SC and Sharman EH. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J Pineal Res 36: 224-231 (2004).
124. Lahiri DK. Where the actions of environment (nutrition), gene and protein meet: Beneficial role of fruit and vegetable juices in potentially delaying the onset of Alzheimer's disease. J Alzheimer's Dis 10:359-361 (2006)
125. Dalman C, Allebeck P, Cullberg J, Grunewald C and Koster M. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiatry 56: 234-240 (1999).
126. Preti A. Fetal hypoxia, genetic risk, and schizophrenia. Am J Psychiatry 160: 1186; author reply 1186 (2003).
127. Bilbo SD, Levkoff LH, Mahoney JH, Watkins LR, Rudy JW and Maier SF. Neonatal infection induces memory impairments following an immune challenge in adulthood. Behav Neurosci 119: 293-301 (2005).
128. Rice DC and Gilbert SG. Effects of developmental exposure to methyl mercury on spatial and temporal visual function in monkeys. Toxicol Appl Pharmacol 102: 151-163 (1990).
129. Lee MH and Rabe A. Premature decline in Morris water maze performance of aging micrencephalic rats. Neurotoxicol Teratol 14: 383-392 (1992).
130. Barone S, Jr., Stanton ME and Mundy WR. Neurotoxic effects of neonatal triethyltin (TET) exposure are exacerbated with aging. Neurobiol Aging 16: 723-735 (1995).
131. Jiang YH, Sahoo T, Michaelis RC, Bercovich D, Bressler J, Kashork CD, et al. A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A. Am J Med Genet A 131: 1-10 (2004).
132. Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, et al . High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J Child Neurol 21: 444-449 (2006).
133. Abdolmaleky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ, et al. Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet 127: 51-59 (2004).
134. Cho HJ, Meira-Lima I, Cordeiro Q, Michelon L, Sham P, Vallada H, et al. Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: a systematic review and meta-analysis. Mol Psychiatry 10: 771-781 (2005).
135. Willis-Owen SA, Turri MG, Munafo MR, Surtees PG, Wainwright NW, Brixey RD, et al. The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. Biol Psychiatry 58: 451-456 (2005).
136. Manuck SB, Flory JD, Ferrell RE and Muldoon MF. Socioeconomic status covaries with central nervous system serotonergic responsivity as a function of allelic variation in the serotonin transporter gene-linked polymorphic region. Psychoneuroendocrinology 29: 651-668 (2004).
137. Sen S, Burmeister M and Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 127: 85-89 (2004).
138. Abdolmaleky HM, Cheng KH, Russo A, Smith CL, Faraone SV, Wilcox M, et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 134: 60-66 (2005).
139. Lahiri DK and Maloney B. Genes are not our destiny: the somatic epitype bridges between the genotype and the phenotype. Nat Rev Neurosci 7:doi:10.1038/nrn2022-c1 (2006).